Virginia Sun1, Jae Y Kim2, Anna Cathy Williams1, Dan J Raz2, Sagus Sampath3, Betty Ferrell1. 1. Division of Nursing Research & Education, Department of Population Sciences, City of Hope, Duarte, California. 2. Division of Thoracic Surgery, Department of Surgery, City of Hope, Duarte, California. 3. Department of Radiation Oncology, City of Hope, Duarte, California.
Abstract
BACKGROUND: Stereotactic body radiotherapy (SBRT) has emerged in recent years as a clinically viable treatment option for early-stage non-small-cell lung cancer (NSCLC) patients. Comprehensive assessment of quality of life (QoL) after SBRT is relatively sparse. OBJECTIVE: To describe QoL and symptoms in a small, prospective cohort of early-stage NSCLC patients treated with SBRT. METHODS: 19 NSCLC patients who were medically unfit for surgery or chose not to undergo surgery were included in the study. All of the patients were treated with SBRT between 2009 and 2013 at a single comprehensive cancer center. Patients completed a baseline assessment of functional and cognitive status, symptoms, psychological distress, and overall QoL. Questionnaires were repeated at 6 and 12 weeks after accrual. RESULTS: There were no significant differences in all outcomes across the 3 evaluation time points. Overall QoL scores were moderate, and the lowest score was observed for the functional well-being domain. The most severe symptoms at baseline were pain, lack of energy, cough, nervousness, difficulty sleeping, shortness of breath, and worry. Severity scores for pain, lack of energy, and cough increased, whereas nervousness, difficulty sleeping, and worry decreased at the 12 week evaluation. LIMITATIONS: Small sample size and lack of sufficient diversity in the cohort. CONCLUSIONS: QoL scores remained relatively stable across time. Anxiety improved after SBRT, whereas symptoms such as generalized pain, lack of energy, and cough worsened. The findings suggest that SBRT is overall a well-tolerated treatment with no significant decrement in patient-centered outcomes.
BACKGROUND: Stereotactic body radiotherapy (SBRT) has emerged in recent years as a clinically viable treatment option for early-stage non-small-cell lung cancer (NSCLC) patients. Comprehensive assessment of quality of life (QoL) after SBRT is relatively sparse. OBJECTIVE: To describe QoL and symptoms in a small, prospective cohort of early-stage NSCLCpatients treated with SBRT. METHODS: 19 NSCLCpatients who were medically unfit for surgery or chose not to undergo surgery were included in the study. All of the patients were treated with SBRT between 2009 and 2013 at a single comprehensive cancer center. Patients completed a baseline assessment of functional and cognitive status, symptoms, psychological distress, and overall QoL. Questionnaires were repeated at 6 and 12 weeks after accrual. RESULTS: There were no significant differences in all outcomes across the 3 evaluation time points. Overall QoL scores were moderate, and the lowest score was observed for the functional well-being domain. The most severe symptoms at baseline were pain, lack of energy, cough, nervousness, difficulty sleeping, shortness of breath, and worry. Severity scores for pain, lack of energy, and cough increased, whereas nervousness, difficulty sleeping, and worry decreased at the 12 week evaluation. LIMITATIONS: Small sample size and lack of sufficient diversity in the cohort. CONCLUSIONS: QoL scores remained relatively stable across time. Anxiety improved after SBRT, whereas symptoms such as generalized pain, lack of energy, and cough worsened. The findings suggest that SBRT is overall a well-tolerated treatment with no significant decrement in patient-centered outcomes.
Authors: Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy Journal: JAMA Date: 2010-03-17 Impact factor: 56.272
Authors: Frank J Lagerwaard; Neil K Aaronson; Chad M Gundy; Cornelis J A Haasbeek; Ben J Slotman; Suresh Senan Journal: J Thorac Oncol Date: 2012-07 Impact factor: 15.609
Authors: David Cella; David T Eton; Diane L Fairclough; Philip Bonomi; Anne E Heyes; Cheryl Silberman; Michael K Wolf; David H Johnson Journal: J Clin Epidemiol Date: 2002-03 Impact factor: 6.437
Authors: Kristi D Graves; Susanne M Arnold; Celia L Love; Kenneth L Kirsh; Pamela G Moore; Steven D Passik Journal: Lung Cancer Date: 2006-11-03 Impact factor: 5.705
Authors: R K Portenoy; H T Thaler; A B Kornblith; J M Lepore; H Friedlander-Klar; E Kiyasu; K Sobel; N Coyle; N Kemeny; L Norton Journal: Eur J Cancer Date: 1994 Impact factor: 9.162
Authors: Suneetha Devpura; Aharon M Feldman; Samuel D Rusu; Essa Mayyas; Avielle Movsas; Stephen L Brown; Andrew Cook; Michael J Simoff; Zhen Sun; Mei Lu; Sean Vance; Munther I Ajlouni; M Salim Siddiqui; Indrin J Chetty; Benjamin Movsas Journal: Adv Radiat Oncol Date: 2021-09-29